Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFC-Only Asthma Drugs Likely To Lose “Essential Use” Designation

Executive Summary

FDA is likely to initiate proceedings to revoke the "essential use" designation for remaining chlorofluorocarbon-propelled asthma drug products following a lack of strong support by FDA's Pulmonary-Allergy Drugs Advisory Committee for continued use of any of the products

You may also be interested in...



FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds

FDA is proposing that seven drugs used in metered-dose inhalers no longer be considered essential for the treatment of asthma and chronic obstructive pulmonary disease. Without such status, the drugs will no longer be exempt from regulations banning the use of chlorofluorocarbons in aerosol containers and will have to come off the market

FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds

FDA is proposing that seven drugs used in metered-dose inhalers no longer be considered essential for the treatment of asthma and chronic obstructive pulmonary disease. Without such status, the drugs will no longer be exempt from regulations banning the use of chlorofluorocarbons in aerosol containers and will have to come off the market

Kos Azmacort HFA Submission In ’07 Could Lead To Removal Of CFC Version

Kos plans to submit an NDA for Azmacort HFA in the second half of 2007, which would likely lead to the removal of CFC-containing Azmacort

Related Content

Topics

UsernamePublicRestriction

Register

PS046072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel